Sammenlign effektivitet/sikkerhet ved gjentatte doser av ferumoksytol med jernsukrose hos pasienter med kronisk nyrekreft med IDA og på hemodialyse
Ferumoksytol for anemi av CKD-forsøk (FAKTA): En fase IV, åpen, multisenterforsøk, med MR-understudie, av gjentatte doser av Ferumoxytol sammenlignet med jernsukrose for behandling av IDA hos CKD-pasienter på hemodialyse
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Montréal, Canada
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) , or speak with your personal physician
-
Montréal, Canada
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Toronto, Canada
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
-
-
Arkansas
-
Pine Bluff, Arkansas, Forente stater, 71603
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
California
-
Azusa, California, Forente stater, 91702
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Beverly Hills, California, Forente stater, 90211
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Los Angeles, California, Forente stater, 90022
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Los Angeles, California, Forente stater, 90095
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Lynwood, California, Forente stater, 90262
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Northridge, California, Forente stater, 91324
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Paramount, California, Forente stater, 90723
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Sacramento, California, Forente stater, 95815
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
San Diego, California, Forente stater, 92123
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
San Gabriel, California, Forente stater, 91776
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Simi Valley, California, Forente stater, 93065
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Whittier, California, Forente stater, 90603
- For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Whittier, California, Forente stater, 90603
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Connecticut
-
Middlebury, Connecticut, Forente stater, 06762
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Florida
-
Coral Springs, Florida, Forente stater, 33071
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Miami, Florida, Forente stater, 33186
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30904
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Macon, Georgia, Forente stater, 31217
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40292
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70112
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Shreveport, Louisiana, Forente stater, 71103
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Massachusetts
-
Framingham, Massachusetts, Forente stater, 01702
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Michigan
-
Pontiac, Michigan, Forente stater, 48341
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Roseville, Michigan, Forente stater, 48066
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Missouri
-
Farmington, Missouri, Forente stater, 63640
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
New York
-
Bronx, New York, Forente stater, 10641
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Brooklyn, New York, Forente stater, 11212
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Ridgewood, New York, Forente stater, 11385
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28805
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18017
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Philadelphia, Pennsylvania, Forente stater, 19144
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
South Carolina
-
Columbia, South Carolina, Forente stater, 29209
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Texas
-
Arlington, Texas, Forente stater, 76015
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Edinburg, Texas, Forente stater, 78539
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Houston, Texas, Forente stater, 78238
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
San Antonio, Texas, Forente stater, 78205
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
San Antonio, Texas, Forente stater, 78229
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
-
-
-
London, Storbritannia
- For additional information regarding investigative sites for this trial , contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
London, Storbritannia
- For additional information regarding investigative sites for this trial, contact 1-877-411-2510 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Viktige inkluderingskriterier inkluderer:
- Menn og kvinner ≥18 år
- Diagnose av CKD
- Personer i dialyse må ha vært i dialyse i minst 3 måneder før screening
- Kvinnelige forsøkspersoner i fertil alder som er seksuelt aktive, må ha en effektiv prevensjonsmetode i minst 1 måned før screening og samtykke i å forbli på prevensjon til fullført deltakelse i studien
Viktige eksklusjonskriterier inkluderer:
- Historie med allergi mot enten oralt eller IV jern
- Kvinnelige forsøkspersoner som er gravide eller har tenkt å bli gravide, ammer innen 3 måneder etter fødselen eller har en positiv serum- eller uringraviditetstest
- Parenteral jernbehandling innen 30 dager før screening eller røde blodlegemer (RBC)/fullblodstransfusjon innen 14 dager før screening eller planlagt under studien
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: BEHANDLING
- Tildeling: TILFELDIG
- Intervensjonsmodell: PARALLELL
- Masking: INGEN
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
EKSPERIMENTELL: Ferumoksytol
Intravenøst (IV) jern
|
IV Ferumoxytol
Andre navn:
|
|
ACTIVE_COMPARATOR: IV Jern sukrose
Intravenøst (IV) jern
|
IV Jern sukrose
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hemoglobinforandringer
Tidsramme: Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
Endringer i gjennomsnittlig hemoglobin mellom baseline og uke 5 for ferumoksytol og jernsukrose i hver behandlingsperiode.
|
Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endringer i transferrinmetning (TSAT)
Tidsramme: Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
Gjennomsnittlig endring i TSAT fra TP-basislinje til uke 5 for hver TP
|
Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
|
Andel forsøkspersoner med en økning i hemoglobin på ≥1,0 g/dL til enhver tid fra TP baseline til uke 5 for hver TP
Tidsramme: Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
Andelen av forsøkspersoner etter gruppe som oppnår en ≥1,0 g/dL økning i hemoglobin på et hvilket som helst tidspunkt i løpet av hver 5-ukers behandlingsperiode.
|
Opptil 6 behandlingsperioder (5 uker per behandlingsperiode)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Macdougall IC, Strauss WE, Dahl NV, Bernard K, Li Z. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Clin Nephrol. 2019 Apr;91(4):237-245. doi: 10.5414/CN109512.
- Macdougall IC, Dahl NV, Bernard K, Li Z, Batycky A, Strauss WE. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. BMC Nephrol. 2017 Apr 3;18(1):117. doi: 10.1186/s12882-017-0523-8. Erratum In: BMC Nephrol. 2018 Apr 26;19(1):97.
Studierekorddatoer
Studer hoveddatoer
Studiestart (FAKTISKE)
Studiestart
Primær fullføring (FAKTISKE)
Primær fullføring
Studiet fullført (FAKTISKE)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (ANSLAG)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (FAKTISKE)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- AMAG-FER-CKD-401
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .